Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection

Clinica Terapeutica

Volumn 159, Issue 1, 2008, Pages 51-55

  Barbaro, Giuseppe ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Arterial hypertension; Cardiovascular disease; Coronary artery disease; Highly active antiretroviral therapy; Human immunodeficiency virus; Myocardial infarction; Vasculitis

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; TENOFOVIR;

ATHEROGENESIS; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG INDUCED DISEASE; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; NEPHROTOXICITY; PATIENT MONITORING; PERIPHERAL VASCULAR DISEASE; REVIEW; VASCULITIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PROTEASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS;

EID: 40549104773     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62
3. Chi D, Henry J, Kelley J, et al. The effect of HIV infection on endothelial function. Endothelium 2000; 7:223-42
4. Berger O, Gan X, Gujuluva C, et al. CXC and CC chemokine receptors on coronary and brain endothelia. Mol Med 1999; 5:795-805
5. van Wanrooij EJ, Happe H, Hauer AD, et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25:2642-7
6. Barbaro G, Barbarini G, Pellicelli AM. HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 2001; 344: 1799-800
7. Twu C, Liu QN, Popik W, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002; 99:14386-91
8. Fiala M, Murphy T, MacDougall J, et al. HAART drugs induces mitochondrial damage and intercellular gaps ans gp120 causes apoptosis. Cardiovascular Toxicol 2005; 4:327-37
9. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhbitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-62
10. Zhong DS, Lu XH, Conklin BS, et al. HIV protease ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22:1560-6
11. Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J AIDS 2005; 40:12-9
12. Johnson RM, Barbarini G, Barbaro G. Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients. AIDS 2003; 17(S1):S77-S82
13. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell response. AIDS 2006; 20:2275-83
14. van Wijk JPH, de Koning EJP, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47:1117-23
15. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004; 110:2204-9
16. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001; 15:329-34
17. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-8
18. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19:927-33
19. Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary calcium score. Clin Infect Dis 2006; 43:1482-9
20. Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20:1941-50
21. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:F123-8
22. Jerico C, Knobel H, Calvo N, et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37:812-7
23. Thiebaut R, Aurillac-Lavignole V, Bonnet F, et al. Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitane Cohort, 1999-2004. AIDS 2005; 19:729-31
24. Roling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretriviral therapy-induced nephropathy. Clin Infect Dis 2006; 42:1488-95
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection EaToHBCiAATPI. Third Report of the national Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421
26. Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationship to insulin resistance and metabolic syndrome. J Hypertens 2003; 21:1377-82
27. Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15:2001-10
28. Volberding P, Murphy R, Barbaro G, et al. The Pavia Consensus Statement. AIDS 2003; 17(S1):S170-S179
29. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86:939-43
30. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarction in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5:329-33
31. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-8
32. Barbaro G, Di Lorenzo G, Cirelli A, et al. An open-label,p rospective,observational study of the incidence of coronary artery disease in patients with HIV receiving highly active antiretroviral therapy. Clin Ther 2003; 25:2405-18
33. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10
34. Klein D, Hurley LB, Quesenberry Jr CP, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J AIDS 2002; 30:471-7
35. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003; 19:449-55
36. Coplan P, Nikas A, Leavit RY, et al. Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in Four Phase III Clinical Trials. AIDS 2001; 15:1584-6
37. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med 2003; 349:1993-2003
38. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35
39. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-86
40. HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Clin Infect Dis 2004; 37:613-27
41. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized,double-blind,placebo-controlled trial. Lancet 2004; 363:429-38
42. Hadigan C, Yawetz S, Thomas A, et al. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med 2004; 140:786-94